BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 19874195)

  • 1. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.
    Li C; Paris O; Siegel S; Roschger P; Paschalis EP; Klaushofer K; Fratzl P
    J Bone Miner Res; 2010 May; 25(5):968-75. PubMed ID: 19874195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
    Roschger P; Manjubala I; Zoeger N; Meirer F; Simon R; Li C; Fratzl-Zelman N; Misof BM; Paschalis EP; Streli C; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone.
    Farlay D; Boivin G; Panczer G; Lalande A; Meunier PJ
    J Bone Miner Res; 2005 Sep; 20(9):1569-78. PubMed ID: 16059629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S; Vai S
    Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration.
    Boivin G; Deloffre P; Perrat B; Panczer G; Boudeulle M; Mauras Y; Allain P; Tsouderos Y; Meunier PJ
    J Bone Miner Res; 1996 Sep; 11(9):1302-11. PubMed ID: 8864905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium is incorporated in different levels into bones and teeth of rats treated with strontium ranelate.
    Oliveira JP; Querido W; Caldas RJ; Campos AP; Abraçado LG; Farina M
    Calcif Tissue Int; 2012 Sep; 91(3):186-95. PubMed ID: 22806682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
    Boivin G; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats.
    Ammann P; Shen V; Robin B; Mauras Y; Bonjour JP; Rizzoli R
    J Bone Miner Res; 2004 Dec; 19(12):2012-20. PubMed ID: 15537445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased strontium uptake in trabecular bone of ovariectomized calcium-deficient rats treated with strontium ranelate or strontium chloride.
    Pemmer B; Hofstaetter JG; Meirer F; Smolek S; Wobrauschek P; Simon R; Fuchs RK; Allen MR; Condon KW; Reinwald S; Phipps RJ; Burr DB; Paschalis EP; Klaushofer K; Streli C; Roschger P
    J Synchrotron Radiat; 2011 Nov; 18(Pt 6):835-41. PubMed ID: 21997907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new treatment for post-menopausal osteoporosis: strontium ranelate.
    Rizzoli R
    J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
    Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
    Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY; Malaise O; Neuprez A; Bruyere O
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.